====== Astrocytoma IDH-mutant Grade 4 ======

{{rss>https://pubmed.ncbi.nlm.nih.gov/rss/search/1NykVtOHbvJ_i0pBZtNvG0Dbv-WiJ3xRwhF-6m6hV8prLPP9zd/?limit=15&utm_campaign=pubmed-2&fc=20230905113119}}
----

----


The [[World Health Organization Classification of Tumors of the Central Nervous System 2021]] defined [[IDH-mutant Astrocytoma]], [[Grade]] 4. However, the understanding of this subtype is still limited. Chen et al. from the [[Peking Union Medical College Hospital]] conducted a [[study]] to describe the features of [[astrocytoma]], [[IDH-mutant]], and [[Grade]] 4, and explored the similarities and differences between histological and molecular subtypes.

Patients who underwent surgery from January 2011 to January 2022, classified as astrocytoma, IDH-mutant, Grade 4 were included in this study. Clinical, radiological, histopathological, molecular pathological, and [[survival]] data were collected for [[analysis]].

Altogether 33 patients with astrocytoma, IDH-mutant, Grade 4 were selected, including 20 with histological and 13 with molecular WHO Grade 4 astrocytoma. Tumor [[enhancement]], intratumoral-[[necrosis]] like presentation, larger [[peritumoral edema]], and more explicit tumor margins were frequently observed in histological WHO Grade 4 astrocytoma. Additionally, molecular WHO Grade 4 astrocytoma showed a tendency for relatively longer [[overall survival]], while a statistical significance was not reached (47 vs. 25 months, p = 0.22). [[TP53]], [[CDK6]], and [[PIK3CA]] alteration was commonly observed, while [[PIK3R1]] (p = 0.033), [[Notch1]] (p = 0.027), and [[Mycn]] (p = 0.027) [[alteration]]s may affect the [[overall survival]] of molecular WHO Grade 4 astrocytomas.

The study scrutinized IDH-mutant, Grade 4 astrocytoma. Therefore, further classification should be considered as the prognosis varied between histological and molecular WHO Grade 4 astrocytomas. Notably, therapies aiming at [[PIK3R1]], [[Notch1]], and [[Mycn]] may be beneficial
((Chen W, Guo S, Wang Y, Shi Y, Guo X, Liu D, Li Y, Wang Y, Xing H, Xia Y, Li J, Wu J, Liang T, Wang H, Liu Q, Jin S, Qu T, Li H, Yang T, Zhang K, Wang Y, Ma W. Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors. Cancer Med. 2023 Sep 5. doi: 10.1002/cam4.6476. Epub ahead of print. PMID: 37667984.)).